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Membrane/lipid rafts (MLRs) are plasmalemmal microdomains that are essential for neuronal signaling 
and synaptic development/stabilization. Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase 
(statins) can disable the N-methyl-D-aspartate (NMDA) receptor through disruption of MLRs and, in 
turn, decrease NMDA-mediated anxiety. This hypothesis will contribute to understanding the critical 
roles of simvastatin in treating anxiety via the NMDA receptor.
Uniterms: Anxiolytic effects. Membrane/lipid rafts. N-methyl-D-aspartate. Simvastatin.
INTRODUCTION
Clinically, simvastatin (SIM) has been widely used 
to reduce serum low-density lipoprotein (LDL) cholesterol 
levels by inhibiting the rate-limiting enzyme 3-hydroxy-
3-methylglutaryl-coenzyme-A (HMG-CoA) reductase 
(Owens, Byrnes, Mackman, 2014). However, SIM also 
has pleiotropic effects, such as anti-inflammatory, anti-
oxidative and immunomodulatory effects (Eger et al., 
2016a, 2016b; Mihos, Pineda, Santana, 2014; Ungureanu 
et al., 2003). Evidence illustrates that SIM reduces the 
risk of ischemic heart disease and cerebrovascular stroke 
and that it has potential applications in multiple sclerosis, 
Parkinson’s disease, and Alzheimer’s disease (Daneschvar, 
Aronson, Smetana, 2015; Friedman et al., 2013; Kataoka 
et al., 2015; Ní Chróinín et al., 2013; Pihl-Jensen, Tsakiri, 
Frederiksen, 2015; Sett, Robinson, Mistri, 2011). Despite 
growing evidence for the role of SIM in treating central 
nervous system (CNS) diseases, there is relatively little 
knowledge of its direct psychoneurological effects on 
central receptors and its association with behavioral 
effects.
In the CNS, cellular cholesterol homeostasis is 
independent of plasma cholesterol levels because blood-
to-brain cholesterol transport is virtually nonexistent 
through the blood-brain barrier (Chobanian, Hollander, 
1962; Dietschy, Turley, 2004). Statins that cross the 
blood-brain barrier could disrupt normal cholesterol 
turnover. As such, SIM, as a lipophilic statin that, can 
cross the blood-brain barrier easily, was recommended 
as the best candidate capable disrupting CNS cholesterol 
homeostasis (Lutjohann et al., 2004; Thelen et al., 
2006). Changes in brain cholesterol metabolism have 
been reported in experimental animals and humans. 
24(S)-Hydroxycholesterol has been used in many 
studies as an indicator of brain cholesterol turnover, as 
it is the by-product of cholesterol metabolism through 
brain-selective cholesterol 24-hydroxylase (CYP46A1) 
and is capable of crossing the blood-brain barrier for 
detection in systemic circulation. Following chronic SIM 
administration, numerous studies identified reductions in 
the plasma and cerebrospinal fluid concentrations of 24(S)-
hydroxycholesterol (Locatelli et al., 2002; Serrano-Pozo et 
al., 2010; Thelen et al., 2006). This is in-line with reduced 
cholesterol elimination in the brain as a result of prolonged 
statin treatment and suggests that statins affect cholesterol 
homeostasis in the brain. However, although the effect 
of SIM on the peripheral pool of cholesterol is well-
established, its effects on CNS cholesterol are less clear. 
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There are literature data demonstrating that SIM 
treatment diminished cholesterol levels in the brain and 
protected neurons in vitro against cell death induced by 
excessive stimulation of NMDA receptors (Kirsch, Eckert, 
Mueller, 2003; Zacco et al., 2003). NMDA receptors 
have been reported to be associated with cholesterol-rich 
membrane microdomains known as membrane/lipid 
rafts (MLRs) that bind specific proteins (Nothdurfter 
et al., 2013). MLRs have been proposed to function as 
platforms that allow the local accumulation of rafts-
associated proteins, promoting interactions among protein 
complexes and modulating neurotransmitter signaling 
(Allen, Halverson-Tamboli, Rasenick, 2007; Resh, 
2004). Accumulating evidence indicates that the precise 
localization of neurotransmitter receptors, transporters, 
ion channels, and other synaptic proteins in MLRs can 
be regulated by cholesterol and this regulation is critical 
for synaptic plasticity (Allen, Halverson-Tamboli, 
Rasenick, 2007; Sebastião et al., 2013). Due to its impact 
on cholesterol synthesis and protein modification, SIM 
perturbs the composition and properties of MLRs (van 
der Most et al., 2009). Thus, treatment with SIM might 
affect the functionality of proteins associated with MLRs, 
such as NMDA receptors (Ponce et al., 2008). In fact, 
alterations in MLRs composition and structure have been 
associated with different pathologies, and therefore, drug-
induced regulation of MLRs composition and structure 
can modulate cell signaling, offering potentially effective 
treatments for a variety of conditions (Escribá et al., 2015; 
Marin et al., 2013; Michel, Bakovic, 2007). 
Our hypothesis provides strong evidence that 
NMDA receptor modulation after SIM treatment could be 
associated with cholesterol-rich membrane microdomains. 
It is well documented that NMDA receptors in the 
brain have a close correlation with anxiety-like activity 
(Bergink, van Megen, Westenberg, 2004; Chojnacka-
Wójcik, Kłodzinska, Pilc, 2001). Modulation of NMDA 
receptors activity after SIM treatment could explain the 
drug’s anxiolytic-like effects (Camargo et al., 2013; 
Carrocini et al., 2012; Cruz et al., 2011; Kilic et al., 2012; 
Pauleti et al., 2013; Santos et al., 2012; Wang et al., 2009; 
Yan et al., 2011). This hypothesis could be supported 
by the fact that altered levels of NMDA receptors in the 
hippocampus and amygdala directly influence anxiety 
behaviors (Barkus et al., 2010; Blundell, Adamec, 2007; 
Masneuf et al., 2014). 
CHOLESTEROL IN THE CNS
Balanced cholesterol homeostasis is an important 
aspect of nervous system function (Mathews et al., 2014). 
The majority of cholesterol is present in myelin sheaths and 
neuronal membranes, in which this lipid fulfills structural 
and functional tasks. Given the crucial role of cholesterol 
in regulating different neuronal processes, eukaryotes 
have developed sophisticated homeostatic mechanisms to 
preserve cholesterol levels in an optimal range in each brain 
region (Saher, Stumpf, 2015; Segatto et al., 2013). Largely, 
cholesterol in the adult brain is metabolically inert. The most 
significant period of high cholesterol synthesis in the CNS 
occurs during active myelination, which occurs in early 
neural development through the action of oligodendrocytes 
(Dietschy, Turley, 2004). The rate of cholesterol synthesis 
decreases significantly after myelination has been 
completed; however, its synthesis continues at a low basal 
level in the mature adult brain. This occurs primarily 
through de novo cholesterol synthesis by astrocytes, 
although neuronal de novo synthesis and reutilization 
of free cholesterol following neuronal death are also 
contributory (Nieweg, Schaller, Pfrieger, 2009). Therefore, 
the CNS does not rely largely on cholesterol from systemic 
circulation due to limited metabolic turnover during 
adulthood and the brain’s inherent capacity to synthesize 
its own cholesterol (Dietschy, Turley, 2004). Consequently, 
reductions in plasma cholesterol concentrations following 
statin treatment are unlikely to acutely disrupt in CNS 
cholesterol homeostasis (Lutjohann et al., 2004; Thelen 
et al., 2006). Thus, chronic statin therapy may be required 
before significant effects on CNS cholesterol levels are 
observed, with reductions in CNS cholesterol possible either 
directly through direct HMG-CoA reductase inhibition 
or indirectly via a “sink effect” (Cibičková, 2011). In 
addition, cholesterol depletion is reported to lead to the 
inhibition of Ca2+ entry induced by NMDA, α-amino-3-
hydroxyl-5-methyl-4-isoxazole-propionate (AMPA), or 
kainate, inferring that MLRs contribute to the regulation of 
ionotropic glutamate receptor function (Frank et al., 2008).
THE CONCEPT OF MLRS/NMDA RECEPTORS
MLRs consist of assemblies of cholesterol, 
sphingolipids including sphingomyelin and gangliosides, 
and certain types of proteins (Fielding, Fielding, 2003). 
They range from a few nanometers to a few hundred 
nanometers in diameter and comprise approximately 
50% of the cellular membrane (Helms, Zurzolo, 2004). 
The most important properties of MLRs are that they are 
small, dynamic, and heterogeneous, and they can include 
or exclude proteins to variable extents (Hanzal-Bayer, 
Hancock, 2007; Simons, Toomre, 2000). MLRs have been 
implicated in various physiological cellular processes, such 
as protein membrane trafficking and signal transduction, 
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and they have been demonstrated to play roles in synaptic 
plasticity and contribute to neuropathologies, such as 
Alzheimer’s disease, Parkinson’s disease, and Huntington 
disease (Hanzal-Bayer, Hancock, 2007; Karasinska, 
Hayden, 2011; Korade, Kenworthy, 2008; Sebastião et 
al., 2013; Simons, Toomre, 2000). Cholesterol is a key 
component of MLRs, as its depletion disrupts MLRs and 
leads to synaptic dysfunction or loss of synapses (Fielding, 
Fielding, 2003; Korade, Kenworthy, 2008; Sebastião et al., 
2013). Cholesterol is responsible for MLRs maintenance in 
a liquid-ordered phase (Marwali et al., 2003). It maintains 
the raft assembly together and serves as a molecular spacer 
between hydrocarbon chains in sphingolipids (Simons, 
Toomre, 2000). Additionally, the interaction of cholesterol 
with distinct classes of membrane proteins within MLRs 
affects the assembly, stability, and function of the proteins 
(Lee, 2004). The two main types of MLRs in mammalian 
cells are planar MLRs and caveolae. As their names 
suggest, planar MLRs are continuous with the membrane, 
whereas caveolae form invaginations. Apart from their 
shape, caveolae and planar rafts can be distinguished by 
their marker proteins, namely: caveolins and flotillin, 
respectively. Flotillin and caveolins recruit other proteins to 
the raft, but they are structurally distinct (Allen, Halverson-
Tamboli, Rasenick, 2007). The relative proportions of 
these components vary greatly depending on the cell and 
membrane type (Epand, 2008; Gallala, Breiden, Sandhoff, 
2011). MLRs are specialized membrane structures that form 
an organized portion of the membrane with concentrated 
signaling molecules and links to the cytoskeleton (Byrum, 
Rodgers, 2015). Synapses, including both pre-synaptic and 
post-synaptic sites, are highly enriched in MLRs. MLRs 
both contribute to neurotransmitter exocytosis in pre-
synaptic terminals, and post-synaptically modulate neuronal 
signaling through clustering of neurotransmitter receptors, 
ion channels, and components of downstream effectors. 
Several studies illustrated that MLRs concentrate many of 
the regulators and ion channels involved in Ca2+ signaling, 
suggesting significant roles of MLRs in modulating Ca2+ 
signaling (Pani, Singh, 2009). 
The NMDA receptor is an ionotropic glutamate 
receptor. Its channel commonly has a high relative 
permeability to Ca2+, and it is blocked in a voltage-
dependent manner by magnesium ions such that at resting 
potential the response is substantially inhibited. Cholesterol 
depletion is reported to lead to an inhibition of Ca2+entry 
induced by NMDA, AMPA, or kainate, inferring that MLRs 
contribute to the regulation of ionotropic glutamate receptor 
function (Egawa et al., 2016; Frank et al., 2008). Numerous 
post-synaptic density proteins such as NMDA (NR1, NR2A 
and NR2B), AMPA (GluR1 and GluR2), and metabotropic 
glutamate receptors (mGluRs) are associated with synaptic 
MLRs, providing a trans-synaptic link between post-
synaptic density proteins and pre-synaptic active zones 
(Egawa et al., 2016; Kumari, Castillo, Francesconi, 2013). 
Accumulating evidence suggests that MLRs clustering 
is a novel mechanism mediating and amplifying trans-
membrane signaling in response to various stimuli in a 
variety of cell types, including lymphocytes, endothelial 
cells, and neurons (Dupree, Pomicter, 2010; Grassme et 
al., 2001; Zhang et al., 2006). These membrane platforms 
can recruit or aggregate various signaling molecules such 
as small G proteins, tyrosine kinases, and phosphatases, 
resulting in the activation of different signaling pathways 
(Zhang et al., 2009). 
MODULATION OF THE ISOPRENOID/CHO-
LESTEROL BIOSYNTHETIC PATHWAY
Statins are the drugs of choice for lowering LDL 
cholesterol and triglyceride levels in patients with 
hypercholesterolemia (Owens, Byrnes, Mackman, 2014). 
The mechanism of action of these drugs is competitive 
and selective inhibition of HMG-CoA reductase, the 
rate-limiting enzyme in cholesterol synthesis, because 
it is responsible for the conversion of HMG-CoA 
to mevalonate, which is a precursor of cholesterol. 
Although inhibition of HMG-CoA reductase by statins 
reduces cholesterol synthesis, a concomitant effect of 
this functional blockade is decreased availability of 
isoprenoids, the major donors of prenyl groups for protein 
prenylation. A branch point downstream of mevalonate 
synthesis draws substrates away from cholesterol synthesis 
and yields the production of non-sterol isoprenoids such as 
farnesyl pyrophosphate (FPP), which can be converted into 
squalene and cholesterol but is also used for the production 
of geranylgeranyl pyrophosphate (GGPP), an important 
component for the localization and function of signaling 
proteins such as Ras (McTaggart, 2006). Small G-proteins 
(the Ras superfamily of small GTPases) comprise a large 
group of molecular switch proteins involved in several 
signaling pathways, reorganization of the cytoskeleton, 
and intracellular membrane trafficking. Although FPP and 
GGPP appear to mediate some of the effects of statins, 
it is likely that the downstream small GTPase family of 
signaling molecules also plays an important role (Houten, 
Frenkel, Waterham, 2003).
The fact  that  more than 300 proteins have 
been identified as prenylation targets complicates 
any prediction of the mechanism by which statins 
and other prenylation inhibitors affect intracellular 
signaling. Inhibition of HMG-CoA reductase results in 
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decreased levels of FPP and GGPP, potentially leading 
to decreased farnesylation and geranylgeranylation 
of proteins. Predictions are further confounded by an 
incomplete understanding of the mechanism by which 
the farnesylation and geranylgeranylation regulate the 
vast number of small GTPases in the context of multiple 
cellular compartments and interacting processes. The 
small GTPases, which include the two major families 
Ras and Rho, are differentially regulated by farnesylation 
and geranylgeranylation, respectively, although some 
exceptions exist (McTaggart, 2006). By facilitating the 
coupling of extracellular signals to intracellular kinase 
activity, both families of GTPases regulate intracellular 
functions.
The inhibition of farnesylation by SIM has been 
associated with the enhancement of long-term potentiation 
between neurons in mice (Mans, McMahon, Li, 2012). 
This study also found that the protective effect of SIM 
treatment was abolished following replenishment of FPP 
but not GGPP. Paradoxically, it has been suggested in 
other studies that the constant production of GGPP, but 
not FPP or cholesterol, is required for neurite outgrowth 
and maintenance, long-term potentiation, and learning, 
possibly suggesting divergent neuroprotective effects 
associated with these two isoprenoid intermediates (Kotti 
et al., 2006). Given the different roles of these compounds, 
known differences in FPP/GGPP ratios across various 
brain regions may subsequently result in different local 
SIM-induced effects within these regions. The mechanisms 
underlying the differential distribution of FPP and GGPP 
across the brain and the interplay with the effects of SIM 
are unknown. However, studies supporting the isoprenoid 
hypothesis were performed using extremely high statin-
concentrations; thus, their clinical significance is debatable. 
The question whether inhibition of prenylation occurs in the 
brain therefore remains open. We believe that more detailed 
research into the pharmacology of statins, particularly 
the concentrations they reach in the CNS and the level at 
which they block the production of cholesterol and various 
isoprenoids in different cell types, may solve this question.
However, the impact of SIM treatment on NMDA 
receptor function/trafficking is most likely related to 
the effects of SIM on protein prenylation, in particular 
proteinfarnesylation. Indeed, activation of the small 
GTPase H-Ras, which depends on farnesylation for 
function, decreases the surface distribution of the NR2 
subunit of the NMDA receptor (Suvarna et al., 2005). 
Ruocco et al. (2007) demonstrated that inhibition of H-Ras 
farnesylation by farnesyltransferase inhibitor treatment 
inhibits NMDA-mediated excitotoxicity in the rat brain. 
By contrast, treatment of hippocampal slices for several 
hours with SIM increases the magnitude of NMDA 
receptor-dependent long-term potentiation, a mechanism 
thought to mediate memory at the cellular level, in the CA1 
region in the brains of young adult C57BL/6 mice (Figure 
1) (Mans, Mcmahon, Li, 2012). Additionally, chronic SIM 
treatment in rats stimulates the production of brain-derived 
neurotrophic factor in the hippocampus after traumatic 
brain injury by activating Akt-mediated signaling (Wu 
et al., 2008), as well as increases NMDA receptor 
levels, promotes neurogenesis, and increases cerebral 
blood flow by up-regulating vascular growth factor, 
synaptophysin, Akt, and ERK (Chen et al., 2003; Wang 
et al., 2009). However, numerous pre-clinical studies led 
to the hypothesis that hypofunctional NMDA receptors 
may also play an important role in the mechanism of 
anxiolytic actions after SIM treatment (Camargo et al., 
2013; Carrocini et al., 2012; Cruz et al., 2011; Pauleti et 
al., 2013; Santos et al., 2012; Wang et al., 2009; Yan et 
al., 2011). Accordingly, the functional consequence of 
such regulation on NMDA receptor function varies on 
the basis of both the identity of the G protein coupled 
receptor, and the cell type in which relevant receptors are 
expressed. Certainly, further studies are needed to identify 
particular small GTPases and related signaling pathways 
that mediate the neuronal effects of SIM.
The studies supporting the isoprenoid hypothesis 
were performed using extremely high statin concentrations, 
and thus, their clinical significance is debatable. The 
question whether inhibition of prenylation occurs in 
the brain therefore remains open. We believe that more 
detailed research into the pharmacology of statins, 
particularly the concentrations they reach in the CNS and 
the level at which they block the production of cholesterol 
and various isoprenoids in different cell types, may solve 
this question.
INVOLVEMENT OF THE NMDA RECEPTOR 
COMPLEX IN ANXIOLYTIC-LIKE EFFECTS
The results of a number of studies performed in 
recent years indicate that glutamatergic neurotransmission 
Simvastatin → Farnesyl Pyrophosphate ↓ → H-Ras ↓ → NMDA receptor ↑
FIGURE 1 - Effects of simvastatin (SIM) on the N-methyl-D-aspartate (NMDA) biosynthesis pathway. Inhibition of H-Ras by SIM 
suggests increased NMDA receptor levels.
Simvastatin treatment reduces the cholesterol content of membrane/lipid rafts, implicating the N-methyl-D-aspartate receptor in anxiety
Braz. J. Pharm. Sci. 2017;53(1):e16102 Page 5 / 15
via ionotropic receptors is involved in the pathophysiology 
of anxiety (Masneuf et al., 2014). The ionotropic glutamate 
receptor family comprises ligand-gated channels divided 
into three groups named after their selective agonists, 
namely NMDA, AMPA, and kainate and their density 
is high in cortical and limbic regions implicated in the 
mediation of fear and anxiety (Bergink, van Megen, 
Westenberg, 2004; Réus et al., 2015). Several binding sites 
for structurally different ligands have been recognized 
within the NMDA receptor, including a high affinity site 
for glutamate and NMDA, a glycine site physiologically 
activated by glycine or D-serine, and a polyamine site 
for putrescine, spermine and spermidine (Hirose et al., 
2015; Mothet, Le Bail, Billard, 2015; Sirrieh, Maclean, 
Jayaraman, 2015). To activate the NMDA receptor, 
both glutamate and glycine sites should be occupied 
simultaneously, and depolarization of the membrane by 
AMPA receptors at the same synapse is required (Dutta et 
al., 2015). Under depolarizing conditions, the blockage 
of ion channels is relieved and the inflow of Na+ and Ca2+ 
ions through the NMDA receptor pore is permitted (Seong, 
Behnia, Carter, 2014). Several studies revealed that MLRs 
concentrate many of the regulators and ion channels 
involved in Ca2+ signaling, suggesting significant roles of 
MLRs in modulating Ca2+ signaling (Marques-da-Silva, 
Gutierrez-Merino, 2012, 2014).
Pre-clinical data indicate that a number of different 
classes of NMDA receptor antagonists, acting at 
specific sites on the NMDA receptor complex, produced 
anxiolytic-like activity in tests of anxiety in rodents. It has 
been reported that a close correlation exists between the 
regulation of NMDA receptors in the brain and anxiety-
like behavior (Bergink, van Megen, Westenberg, 2004). 
By applying the selective NMDA receptor antagonist 
(±)-2-amino-5-phosphonopentanoic acid into the 
hippocampus, a profound increase in activity was observed 
in the open arms of an elevated plus-maze, strongly 
suggesting that the up-regulation of NMDA receptors 
due to the blockage in the hippocampus mediates an 
anxiolytic-like effect (Nascimento Häckl, Carobrez, 2007). 
The elevated plus-maze is a widely used animal model of 
anxiety that is based on two conflicting tendencies, namely 
the rodent’s drive to explore a novel environment and its 
aversion to open spaces. Thus, anxious animals will spend 
most of their time in the closed arms, whereas less anxious 
animals will explore open areas for longer period of time 
(Pellow et al., 1985). A similar result was also found in 
Rainnie’s study illustrating that long-lasting anxiety-like 
behavior in rats was eliminated by applying an NMDA 
receptor antagonist into the basolateral complex of the 
amygdala (Rainnie et al., 2004). It appears that treatment 
with an NMDA receptor antagonist such as dizocilpine 
in rodents could reduce anxiety behavior (Ma, Leung, 
2007). Moreover, the anxiolytic effect obtained after the 
microinjection of spermine into the periaqueductal gray 
matter was blocked by pretreatment with a polyamines 
antagonist, such as arcaine or ifenprodil, at the same site 
(Cruz, Carobrez, 2006). These results demonstrate that 
other modulatory sites on the NMDA receptor complex 
may be targeted to alter anxiety in addition to direct 
antagonism of the NMDA pore region or glutamate-
binding site. Reduction of the availability of NMDA 
receptors to interact with NMDA or its physiological 
ligand glutamate is one mechanism that might mediate 
the anxiolytic activity of SIM. Our results also provide 
strong evidence that chronic high-dose SIM administration 
has NMDA antagonist-like effects, which would partially 
explain the anxiolytic effects of this drug (Camargo et al., 
2013; Carrocini et al., 2012; Cruz et al., 2011; Pauleti et 
al., 2013; Santos et al., 2012).
SIM TREATMENT EXERTS ANXIOLYTIC-LIKE 
EFFECTS
Our results suggest that sub-chronic treatment with 
SIM reduced anxiety levels in male Wistar rats when 
combined with environmental enrichment (Cruz et al., 
2011; Camargo et al., 2013). Music exposure combined 
with SIM treatment increased the percentage of time spent 
and entries into the open arms of the elevated plus-maze 
(Table 1). These two studies reached the same conclusion 
that SIM combined with music has anxiolytic-like 
effects in the elevated plus-maze. A possible mechanism 
mediating these effects could involve NMDA receptor 
modulation. These results indicate that music can serve 
as an effective adjuvant in rats treated with SIM and that 
this species could potentially be used in other pre-clinical 
models utilizing musical interventions (Cruz et al., 2015).
Prolonged administration of different classes 
of drugs may produce convergent effects on different 
neurotransmit ter  systems or  s ignal ing targets . 
Unfortunately, little information is available regarding 
neurotransmitter substrates that are critical for the 
behavioral effects of different types of drugs in animal 
models. In addition, data accumulated in the last decade 
indicate that NMDA receptors may be involved in the 
pathophysiology of depression and the mechanism of 
action of antidepressants (Szasz et al., 2007). These 
data suggest that the inhibitory effect of fluoxetine is 
exerted directly on NMDA receptors, contributing to 
the therapeutic effects of this drug. Pre-clinical data 
demonstrated that blocking the NMDA receptor complex 
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produced anxiolytic and antidepressant activity in animal 
tests (Pittenger, Sanacora, Krystal, 2007; Riaza Bermudo-
Soriano et al., 2012). The results of our experiments 
suggest that sub-chronic treatment with SIM reduces 
anxiety levels in rats when administered with fluoxetine 
(Santos et al., 2012). The experimental groups orally 
administered 10 mg/kg SIM combined with 10 mg/kg 
fluoxetine exhibited increased time spent in the open 
arms of the elevated plus-maze (Table II). These results 
strongly indicate that SIM treatment combined with 
fluoxetine improves the ability to cope with aversive 
situations, thus leading to a reduced anxiety level and 
playing an important role in the synergistic effect of 
combination therapy (Santos et al., 2012; Gougol et al., 
2015). A possible mechanism mediating these effects may 
involve modulation of NMDA receptors by the cholesterol 
distribution within brain cell membranes (Kirsch, Eckert, 
Mueller, 2003; Ponce et al., 2008). However, the possible 
involvement of MLRs in NMDA receptor function and 
its modulation by fluoxetine could not be confirmed. In 
addition, the impairment of MLRs integrity by cholesterol 
depletion did not affect the modulatory potency of 
desipramine at the NMDA receptor, suggesting that the 
membrane localization of this receptor and compound 
plays a minor role for its modulation by this antidepressant 
(Nothdurfter et al., 2013).
Benzodiazepines are the most frequently used 
psychotropic agents and the mainstay of drug treatment 
for anxiety disorders. The elevated plus-maze test is a 
task that reliably detects the anxiolytic effect of clinically 
TABLE I – Effect of simvastatin (SIM, 1 and 10 mg/kg oral) on anxiety-like behavior in rats under each sound condition (silence 
and music) in the elevated plus-maze – percent time spent in the open arm and percent frequency of open arm entries. Values are 
expressed as the mean ± standard error of the mean; n = 10, *p<0.05, **p<0.01, and ***p<0.001. Statistically significant compared 
to the vehicle-silence group (analysis of variance [ANOVA] followed by the Newman-Keuls test)
Treatment %Time spent in the open arm 
(ANOVA → F = 4.160; p<0.01)
% Frequency of open arm entries 
(ANOVA → F = 5.483; p<0.001)
Silence
Vehicle 11.5 ± 2.1 22.5 ± 6.2
SIM 1 mg/kg 16.6 ± 1.7 28.4 ± 6.6
SIM 10 mg/kg 33.1 ± 3.6 31.1 ± 6.4
Music
Vehicle 25.3 ± 2.9 28.6 ± 5.0
SIM 1 mg/kg 40.0 ± 5.2* 43.7 ± 4.7***
SIM 10 mg/kg 36.3 ± 3.0* 34.9 ± 4.9**
Source: (Camargo et al., 2013).
TABLE II – Behavioral responses of rats in the elevated plus-maze following sub-chronic simvastatin (SIM) treatment combined 
with fluoxetine (Flu) - percent time spent in the open arm and percent frequency of open arm entries. Values are expressed as the 
mean ± standard error of the mean; n = 8, **p<0.01. Statistically significant compared to the vehicle group (analysis of variance 
[ANOVA] followed by the Newman-Keuls test)
Treatment %Time spent in the open arm 
(ANOVA → F = 4.979; p<0.001)
% Frequency of open arm entries 
(ANOVA → F = 2.207; p>0.05)
Vehicle 10.5 ± 5.0 48.0 ± 4.0
SIM 1 mg/kg 18.0 ± 7.0 56.5 ± 3.5
SIM 10 mg/kg 28.5 ± 2.0 54.8 ± 6.0
Flu 2 mg/kg 17.7 ± 8.0 51.7 ± 9.0
SIM 1 mg/kg + Flu 2 mg/kg 11.8 ± 2.0 42.1 ± 3.0
SIM 10 mg/kg + Flu 2 mg/kg 27.4 ± 3.0 54.8 ± 2.5
Flu 10 mg/kg 27.3 ± 9.0 53.3 ± 8.0
SIM 1 mg/kg + Flu 10 mg/kg 13.9 ± 4.0 41.8 ± 4.0
SIM 10 mg/kg + Flu 10 mg/kg 41.2 ± 7.0** 48.0 ± 4,5
Source: (Santos et al., 2012) 
Simvastatin treatment reduces the cholesterol content of membrane/lipid rafts, implicating the N-methyl-D-aspartate receptor in anxiety
Braz. J. Pharm. Sci. 2017;53(1):e16102 Page 7 / 15
relevant benzodiazepines, such as diazepam that display 
anxiolytic-like behavioral profile including increases in the 
percentage of entries into and time spent in the open arms 
of the maze (Zhou et al., 2015). Our results suggest that 
sub-chronic treatment with SIM reduces anxiety levels in 
mice when combined with diazepam (Pauleti et al., 2013). 
Diazepam combined with SIM increases the percentage of 
time spent and entries into the open arms of the elevated 
plus-maze (Table III). Additionally, SIM could potentiate 
the anxiolytic-like effects of diazepam. In mammals, 
the involvement of excitatory glutamate and inhibitory 
gamma (γ)-aminobutyric acid (GABA) in the amygdala 
is particularly important for controlling levels of fear and 
anxiety (Bian, 2013). The NMDA receptor has also been 
directly implicated in the emergence of gamma rhythms, 
as NMDA receptor antagonists can disrupt or potentiate 
gamma rhythms in vivo (Pinault, 2008). Pre-synaptically, 
NMDA receptors may participate in neurotransmitter 
release, a process dependent on Ca2+ ions, whereas post-
synaptically, their location on GABAergic neurons may 
contribute to the regulation of inhibitory tone and normal 
oscillatory activity in the brain (Deutsch et al., 2010). 
Therefore, NMDA receptors contribute to the regulation of 
central inhibitory tone by influencing the firing of GABA-
inhibitory neurons. In addition to NMDA receptors, other 
receptors on the surface of GABA-inhibitory neurons 
may represent promising pharmacotherapeutic targets. 
Consistent with this hypothesis, blockade of the NMDA 
receptor complex and/or activation of benzodiazepine 
receptors mediated anxiolytic activity in elevated 
plus-maze tests induced, by the co-administration of 
SIM and diazepam. Additionally, the localization of 
NMDA receptors within the MLRs appears to depend 
on the respective GABAA receptor subunit composition 
(Nothdurfter et al., 2013).
Several studies identified ethanol as a potent and 
selective inhibitor of NMDA receptors, and prolonged 
ethanol exposition leads to a compensatory up-regulation 
of these receptors, resulting in enhanced NMDA receptor-
mediated functions after ethanol withdrawal. These 
alterations are believed to contribute to the development 
of ethanol tolerance and, dependence as well as the acute 
and delayed signs of ethanol withdrawal (Nagy, 2004). 
In particular, the up-regulation of different subunits of 
the NMDA receptor may cause hyperexcitability of the 
CNS during withdrawal or negative emotions such as 
dysphoria, irritability, anxiety, and depression (Blanco-
Gandía et al., 2015). In accordance with numerous data in 
the literature, ethanol withdrawal induces an anxiogenic 
effect in the elevated plus-maze (Kumar et al., 2013; Van 
Skike, Diaz-Granados, Matthews, 2015). However, these 
findings contrast our previous data indicating that lower 
doses of ethanol produce anxiolytic-like effects (Cruz et 
al., 2012a). Therefore, negative modulators of NMDA 
receptors may be useful for the pharmacotherapy of 
alcoholism, attenuating both the physical symptoms and 
TABLE III - Behavioral responses of mice in the elevated plus-maze following sub-chronic simvastatin (SIM) treatment combined 
with diazepam (DZP) - percent time spent in the open arms and percent frequency of arms entries. Values are expressed as the 
mean ± standard error of the mean; n = 8, *p<0.05, **p<0.01, and ***p<0.001. Statistically significant compared to the vehicle 
group (analysis of variance [ANOVA] followed by the Newman-Keuls test)
Treatment %Time spent in the open arm 
(ANOVA → F = 6.858; p<0.001)
% Frequency of open arm entries 
(ANOVA → F = 9.614; p<0.001)
Vehicle 1.5 ± 0.5 3.2 ± 1.0
SIM 1 mg/kg 12.1 ± 1.0** 31.8 ± 4.5*
SIM 10 mg/kg 10.0 ± 0.8** 14.0 ± 5.0
DZP 0.5 mg/kg 28.9 ± 2.0** 52.2 ± 8.0**
SIM 1 mg/kg + DZP 0.5 mg/kg 27.8 ± 1.5** 48.1 ± 6.0**
SIM 10 mg/kg + DZP 0.5 mg/kg 41.6 ± 1.6** 52.4 ± 4.0**
DZP 1 mg/kg 50.3 ± 2.0*** 74.8 ± 11.0***
SIM 1 mg/kg + DZP 1 mg/kg 57.0 ± 2.5*** 45.4 ± 13.0**
SIM 10 mg/kg + DZP 1 mg/kg 88.6 ± 2.7*** 92.5 ± 7.0***
DZP 2 mg/kg 60.2 ± 3.0*** 69.7 ± 6.8***
SIM 1 mg/kg + DZP 2 mg/kg 57.0 ± 5.0*** 60.2 ± 7.3***
SIM 10 mg/kg + DZP 2 mg/kg 73.4 ± 3.5*** 75.6 ± 5.0***
Source: (Pauleti et al., 2013) 
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some affective and motivational components of alcohol 
withdrawal. The results of our experiments suggest that 
sub-chronic treatment with SIM reduces anxiety-like 
behavior in ethanol-withdrawn rats (Carrocini et al., 
2012). These symptoms were observed as increases in 
the percentage of time spent in and entries into the open 
arms of the elevated plus-maze (Table IV). The evidence 
supporting the effects of SIM treatment on NMDA 
receptor binding density in the brain reveals a possible 
NMDA antagonist-like effect, which provides an exciting 
and potential paradigm for decreasing anxiety (Yan et al., 
2011; Wang et al., 2009). Cholesterol depletion is reported 
to lead to an inhibition of Ca2+ entry induced by NMDA, 
AMPA, or kainate, inferring that MLRs contribute to 
the regulation of ionotropic glutamate receptor function 
(Frank et al., 2008). Therefore, treatment with SIM might 
affect the functionality of proteins associated with MLRs, 
such as NMDA receptors.
These findings will contribute to a better understanding 
of the critical roles of SIM in treating anxiety, demonstrating 
that reducing cholesterol levels protects against NMDA-
induced anxiety, probably by suppressing the association of 
NMDA receptors with MLRs. Changes in brain cholesterol 
metabolism have been reported in experimental animals and 
humans, sometimes following short-term statin treatment. 
It is possible that SIM affects neuronal cholesterol levels 
soon after the beginning of treatment (Locatelli et al., 2002; 
Thelen et al., 2006).
ORCHESTRATION OF NMDA RECEPTOR 
SIGNALING BY SIM
Statins have been demonstrated to act through 
cholesterol-dependent and independent mechanisms, 
and they can affect several tissue functions and modulate 
specific signal transduction pathways that could explain 
their pleiotropic effects. Cholesterol appears to be essential 
for the stability and functionality of MLRs. The inhibition 
of HMG-CoA reductase by SIM disrupts the distribution 
of signaling molecules within rafts, resulting in a reduced 
association of an NMDA receptor subunit with MLRs, 
although no change was found in the total level of this 
NMDA receptor subunit (Kirsch, Eckert, Mueller, 2003; 
Ponce et al., 2008; Wang et al., 2009). As a possible 
mechanism of the anxiolytic-like effect of SIM based 
on our data, we propose that the reduction of the level of 
membrane cholesterol decreases transporter-mediated 
glutamate release from nerve terminals (Camargo et al., 
2013; Carrocini et al., 2012; Cruz et al., 2011; Pauleti et 
al., 2013; Santos et al., 2012). This does not contradict the 
NMDA-dependent and non-sterol mechanisms of action of 
SIM (there may be additive or synergetic effect). It is well 
documented that NMDA receptors in the brain have a close 
correlation with anxiety-like activity (Bergink, van Megen, 
Westenberg, 2004; Réus et al., 2015). It is highly probable 
that inhibition of NMDA receptor down-regulation in the 
hippocampus and basolateral complex of the amygdala 
mediate the anxiolytic effects of SIM (Yan et al., 2011, 
Wang et al., 2009). Accordingly, NMDA, AMPA, and 
metabotropic glutamate receptors are regulated by MLRs-
related pathways (Francesconi, Kumari, Zukin, 2009; Hou 
et al., 2008; Swanwick et al., 2009).
However, the cholesterol synthesis pathway also 
has several by-products, including non-sterol isoprenoids 
that are important in cellular functioning (McTaggart, 
2006). The impact of SIM treatment on NMDA receptor 
function/trafficking is most likely related to its effects on 
protein prenylation, in particular protein farnesylation 
(Mans, Mcmahon, Li, 2012). It is worth noting that 
SIM treatment can enhance NMDA receptor activity by 
TABLE IV - Behavioral responses in the elevated plus-maze following sub-chronic simvastatin (SIM) treatment in rats with ethanol 
(EtOH) withdrawal syndrome - percentage of time spent in the open arm and percentage of frequency of open arm entries. Values 
are expressed as the mean ± standard error of the mean; n = 10, *p<0.05. Statistically significant compared to the vehicle group 
(analysis of variance [ANOVA] followed by the Newman-Keuls test)
Treatment %Time spent in the open arm 
(ANOVA → F = 3.183; p<0.05)
% Frequency of open arm entries 
(ANOVA → F = 1.469; p>0.05)
Vehicle 6.9 ± 2.0 19.6 ± 3.8
SIM 1 mg/kg 18.6 ± 4.6* 25.9 ± 4.3
SIM 10 mg/kg 12.1 ± 2.8 32.7 ± 4.3
EtOH 4.0 ± 1.6 28.1 ± 4.0
SIM 1 mg/kg + EtOH 23.4 ± 4.6* 30.9 ± 5.2
SIM 10 mg/kg + EtOH 17.3 ± 4.9 22.1 ± 4.8
Source: (Carrocini et al. (2012) 
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reducing FPP levels (Chen et al., 2016; Mans, Mcmahon, 
Li, 2012; Parent et al., 2014). These data strongly 
implicate SIM-induced changes in neuronal function 
via isoprenoid-mediated modulation of small GTPases. 
Indeed, activation of the small GTPase H-Ras, which 
depends on farnesylation for function, decreases the 
surface distribution of the NR2 subunit of the NMDA 
receptor (Suvarna et al., 2005). Accordingly, deletion 
of H-Ras increases NMDA receptor-dependent synaptic 
conductance (Manabe et al., 2000).
Studies supporting the isoprenoid hypothesis were 
performed using extremely high statin concentrations; 
thus, their clinical significance is debatable. The question 
whether inhibition of prenylation occurs in the brain 
therefore remains open. On the contrary, although the 
effect of statins on the peripheral pool of cholesterol is 
well-established, their effects on CNS cholesterol are less 
clear. The CNS does not rely largely on cholesterol from 
systemic circulation due to limited metabolic turnover 
during adulthood and the brain’s inherent capacity to 
synthesize its own cholesterol (Dietschy, Turley, 2004). 
As such, reductions in plasma cholesterol concentrations 
following statin treatment are unlikely to acutely disrupt 
in CNS cholesterol homeostasis (Lutjohann et al., 2004; 
Thelen et al., 2006). Unlike cholesterol in plasma, which has 
a half-life of only a few days, brain cholesterol has a half-
life of 6 months to 5 years (Dietschy, Turley, 2004). Thus, 
chronic statin therapy may be required before significant 
effects on CNS cholesterol are observed, with reductions in 
CNS cholesterol content possibly occurring either directly 
through direct HMG-CoA reductase inhibition or indirectly 
via a “sink effect” (Cibičková, 2011). There exists much 
controversy regarding the effects of statins on neuronal 
function (Cruz et al., 2012b). We believe that more detailed 
research into the pharmacology of statins, particularly 
the concentrations they reach in the CNS and the level at 
which they block the production of cholesterol and various 
isoprenoids in different cell types, may solve this question. 
In summary, if our speculation is correct, this finding 
presents a novel point that sub-chronic treatment with 
SIM results in an anxiolytic effect, probably by reducing 
the association of NMDA receptors with MLRs. These 
novel results could have significant implications for our 
understanding of the influence of cholesterol-lowering 
agents such as SIM on the organization and function of the 
NMDA receptor, an important neurotransmitter receptor. 
In this study, we reviewed the mechanism by which 
membrane lipids, which play roles in the membrane’s 
function as a barrier and signaling medium, contribute 
to anxiety. Understanding the molecular mechanisms 
by which lipids change and affect this disorder will be 
of great benefit to biology and pharmacology in cases in 
which lipids and lipid-affecting drugs might be used as 
clinically. However, more evidence is required before 
any SIM therapy can be recommended clinically in the 
treatment or prevention of anxiety.
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